Loading...
Loading...
- Novo Nordisk A/S NVO reported Q4 FY22 sales of DKK 48.09 billion, up 25% Y/Y (+18% on constant currency), driven by Diabetes care sales growth of 14% (CER) and Obesity care sales growth of 84% (CER).
- Net profit increased from DKK 10.89 billion to DKK 13.59 billion.
- Operating profit increased from DKK 13.64 billion to DKK 17.09 billion, but the margin remained unchanged at 35% from a year ago.
- Novo Nordisk said it expected "periodic supply constraints" this year, partly driven by higher-than-expected demand for its diabetes drug, Ozempic, and manufacturing constraints.
- Outlook: Novo Nordisk expects sales and operating profit growth in local currencies in 2023 to be between 13% and 19%.
- "Hopefully, we'll get a whole year where Wegovy sales are allowed to flourish, so that's definitely something that pulls up the guidance for 2023," Laustsen told Reuters.
- Sales of the company's new obesity drug, Wegovy, grew over 200% to DKK 2.5 billion despite some supply-related hiccups.
- The company expects to invest around DKK 25 billion in 2023, mainly toward additional ingredient production and fill-finish capacity.
- Novo Nordisk will propose a dividend of 8.15 crowns per share, making the total dividend for 2022 DKK 12.4 per share. The Board of Directors has decided to initiate a new 12-month share repurchase program of up to DKK 28 billion.
- Price Action: NVO shares are down 1.04% at $137.33 during the premarket session on the last check Wednesday.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in